New immune oncology drug molecules expected to result from leadXpro / InterAx partnership

Wednesday, April 18, 2018 @ 12:00 am

See the media release below on leadXpro AG and InterAx Biotech AG, joining forces to discover and optimize new drug lead molecules targeting G-protein coupled receptors.

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Celonic leverages micro-bioreactor platform for perfusion-based bioprocessing

Celonic Group leverages Merck’s Breez micro-bioreactor technology to optimize bioprocessing efficiency and scalability. This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies. Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in red
March 12, 2025

Torqur: Interim Phase 2 clinical trial results for Actinic keratosis treatment

Full study results are expected in June 2025, but early results demonstrate strong potential; 60% of trial patients experienced full or partial lesion clearance.
March 10, 2025

Volv Global expands to power AI innovation in healthcare

Volv Global has more than doubled its office space for the fourth year in a row to support a rapidly growing international team. Expansion driven by accelerating demand for its proprietary AI-driven healthcare insights. New space fosters collaboration, innovation, and impact—driving precision in difficult-to-diagnose diseases.
March 5, 2025

Adoram Therapeutics secures pre-seed investment

Adoram Therapeutics Secures Pre-Seed Investment to Advance Innovative Cancer Immunotherapy and Inflammation Programs
March 3, 2025

Pharvaris: Long-term clinical data for prevention and treatment of hereditary angioedema attacks

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of life Ongoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time
March 3, 2025